MiMedx Group, Inc. (MDXG)
MiMedx Group, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
MiMedx Group, Inc. (MDXG) is a Biotechnology company based in US with a market capitalization of $643.4M. Revenue grew 20.0% year-over-year and the company generated $73M in free cash flow. This page tracks MDXG's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 837 employees · IPO Feb 12, 2008
Valuation
Valuation & price
$3.56as of May 17, 2026· -55.3% vs 52w high
11.0
P/E ratio
Latest-FY diluted EPS
2.51
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$643.4M
Market cap
20.0%
Revenue growth (YoY)
82.6%
Gross margin
$73M
Free cash flow (USD)
-$143.6M
Net debt
Net cash position
0.6%
Share dilution
3/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed Apr 29, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is MiMedx Group, Inc.'s market cap?
MiMedx Group, Inc. (MDXG) has a market capitalization of $643.4M.
What is MDXG's P/E ratio?
MDXG trades at a price-to-earnings ratio of 11.0, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is MDXG's price-to-book (P/B) ratio?
MDXG trades at 2.51 times book value per share.
Are insiders buying MDXG stock?
SEC Form 4 filings show no open-market insider buys at MiMedx Group, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.